PMAM
ATNM icon

Picton Mahoney Asset Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Picton Mahoney Asset Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,993
Closed -$21K – 978
2025
Q1 		$21K Buy
12,993
+7,025
+118% +$8.92K ﹤0.01% 564
2024
Q4 		$7K Buy
+5,968
New +$9.26K ﹤0.01% 562

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return

Picton Mahoney Asset Management's ATNM Position: Q2 2025 in Review

Picton Mahoney Asset Management sold out of Actinium Pharmaceuticals (ATNM) in Q2 2025, closing a stake of 12,993 shares — an estimated $21K sold.

Picton Mahoney Asset Management first reported a position in ATNM in Q4 2024 and held it in 2 quarters. The position peaked at $21K in Q1 2025. 63 funds tracked by Wall St. Rank hold ATNM as of Q2 2025.

  • Picton Mahoney Asset Management reported no remaining Actinium Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 12,993 Actinium Pharmaceuticals shares in Q2 2025, an estimated $21K.
  • Picton Mahoney Asset Management first reported a position in Actinium Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Picton Mahoney Asset Management's Actinium Pharmaceuticals position peaked at $21K in Q1 2025.
  • 63 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2025.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.